The Priority Review

Clinical trials Brief

GlaxoSmithKline registers Phase 3 linerixibat safety eXtension study in Japan

The study plans to enroll 40 participants and start on October 9, 2026. It aims to assess the long-term safety of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and efficacy study, LLSAT (NCT04167358).

Primary source

ClinicalTrials.gov registry record, October 6, 2026

J-LINX: Japan LINerixibat eXtension Study

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation